文献速递炎症性肠病消化内镜

胶囊内镜与粪便生物标志物在小肠克罗恩病缓解评估及复发预测中的作用

Role of capsule endoscopy and fecal biomarkers in small-bowel Crohn's disease to assess remission and predict relapse.
PubMed 文献 · Gastrointest Endosc · 2017-09-22

43例临床缓解的小肠克罗恩病患者前瞻性纳入4个学术中心并随访12个月,基线胶囊内镜显示60%存在黏膜炎症,其与粪便钙卫蛋白、乳铁蛋白和S100A12相关,但与CDAI和C反应蛋白无关;随访期间14%出现临床复发,复发者均有黏膜炎症且83%基线钙卫蛋白和乳铁蛋白升高。

要点

  • 临床缓解的小肠克罗恩病患者中60%胶囊内镜仍见黏膜炎症。
  • 黏膜炎症者85%基线粪钙卫蛋白升高、77%乳铁蛋白升高。
  • 随访12个月14%出现临床复发,复发者均有黏膜炎症。

核心结论

  • 临床缓解的小肠克罗恩病患者中许多经胶囊内镜和粪便生物标志物评估仍存在黏膜炎症,仅部分在中期随访中出现临床复发,提示胶囊内镜和粪便生物标志物有助于监测小肠克罗恩病进展。

研究设计与样本

  • 前瞻性纳入4个学术中心的43例临床缓解(克罗恩病活动指数CDAI<150)成人小肠克罗恩病患者,临床随访12个月,基线胶囊内镜采用胶囊内镜评分指数(CESI或Lewis评分)评分,并检测基线和终点粪便生物标志物。

主要发现

  • 胶囊内镜结果正常17例(40%),轻度炎症19例(44%),中重度炎症7例(16%)。
  • 26例(60%)胶囊内镜见黏膜炎症者中,85%基线粪钙卫蛋白升高,77%乳铁蛋白升高。
  • 无炎症患者钙卫蛋白和乳铁蛋白均正常,中重度炎症患者两者均升高。
  • CESI与钙卫蛋白、乳铁蛋白和S100A12水平显著相关,但与CDAI或C反应蛋白无关。
  • 随访期间14%患者出现临床复发,均有胶囊内镜黏膜炎症,83%基线钙卫蛋白和乳铁蛋白升高。

临床怎么用

  • 原文结论认为胶囊内镜和粪便生物标志物有助于监测小肠克罗恩病进展,未据此给出具体推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Capsule endoscopy (CE) is the most sensitive test to diagnose small-bowel Crohn's disease (CD). Conventional parameters poorly assess CD remission, and although fecal biomarkers assess colonic activity, their role in assessing remission is uncertain. We report CE findings in small-bowel CD patients in clinical remission compared with fecal biomarkers and standard clinical tools to determine mucosal remission and predict relapses. METHODS: Forty-three adult small-bowel CD patients in clinical remission (Crohn's Disease Activity Index [CDAI] <150) were prospectively enrolled at 4 academic centers and followed clinically for 12 months. Baseline CE studies were scored using the Capsule Endoscopy Scoring Index (CESI or Lewis score). Baseline and endpoint fecal biomarkers were assayed. RESULTS: CE findings were normal in 17 patients (40%), mild inflammation in 19 (44%), and moderate to severe inflammation in 7 (16%). Of the 26 patients (60%) with mucosal inflammation on CE, 85% had elevated baseline fecal calprotectin and 77% elevated lactoferrin level. Calprotectin and lactoferrin were normal in all patients without inflammation and elevated in all with moderate to severe inflammation. CESI correlated significantly with calprotectin, lactoferrin, and S100A12 levels but not either CDAI or C-reactive protein. During follow-up, 14% of patients exhibited a clinical flare; all had mucosal inflammation at CE and 83% had elevated baseline calprotectin and lactoferrin levels. CONCLUSIONS: In small-bowel CD patients in clinical remission, many had ongoing mucosal inflammation assessed by CE and fecal biomarkers. Only some developed a clinical flare during medium-term follow-up. These findings suggest CE and fecal biomarkers are useful in monitoring small-bowel CD progress.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Aggarwal V, Day AS, Connor S, et al. Role of capsule endoscopy and fecal biomarkers in small-bowel Crohn's disease to assess remission and predict relapse. Gastrointest Endosc. 2017. PMID: 28947363. doi:10.1016/j.gie.2017.09.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。